Brief: Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication
Wed 05:39
BRIEF-Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication Oct 21 (Reuters) - FORMYCON AG FYB.DE:
FORMYCON AND BIOCELYS COMBINE COMPLEMENTARY DEVELOPMENT AND MANUFACTURING EXPERTISE IN NEW BIOSIMILAR PROJECT FYB286
FYB286 EXPANDS FORMYCON BIOSIMILAR PIPELINE TARGETING NICHE INDICATION
AND BIOCELYS LAUNCH COLLABORATION TO DEVELOP BIOSIMILAR FYB286
TO RECEIVE COMPENSATION AND LOW DOUBLE-DIGIT SHARE OF FUTURE SANTO REVENUES
SANTO BIOSIMILAR PROVIDES UPFRONT FINANCING FOR FYB286 PROJECT
Source text: ID:nEQ8JbtySa
Further company coverage: FYB.DE
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Formycon AG
See all newsBrief: Formycon Says Fyb286 Expands Formycon Biosimilar Pipeline Targeting Niche Indication
Brief: FORMYCON AG - ENTERS COOPERATION AGREEMENTS WITH BIOCELYS AND SANTO BIOSIMILAR FOR BIOSIMILAR CANDIDATE
Brief: Formycon And Zydus Say FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
Brief: Formycon AG - Clinical Development Of FYB206 Completed In July 2026
Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows